Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial

BMC Nephrology
Arun SedhainAnil Baral

Abstract

The management of proliferative lupus nephritis (LN) comprises timely and coordinated immunosuppressive therapy. This study aimed to evaluate and compare the effectiveness and safety profile of low dose mycophenolate mofetil (MMF) and cyclophosphamide (CYC) in induction therapy of LN in Nepalese population. We conducted a prospective, open-label, randomized trial over a period of one and half years. Forty-nine patients with class III to V lupus nephritis were enrolled, out of which 42 patients (21 in each group) could complete the study. CYC was given intravenously as a monthly pulse and MMF was administered orally in the tablet form in the maximum daily dose of 1.5 g in two divided doses. The mean age of the patients was 25.43 ± 10.17 years with female to male ratio of 7.3:1. Mean baseline serum creatinine was 1.58 ± 1.38 mg/dL and eGFR was 62.38 ± 26.76 ml/min/1.73m2. Mean 24-h urinary protein was 4.35 ± 3.71 g per 1.73 m2 body surface area. At 6 months, serum creatinine (mg/dL) decreased from 1.73 to 0.96 in CYC and from 1.24 to 0.91 in the MMF group with improvement in eGFR (ml/min/1.73 m2) from 60.33 to 88.52 in CYC and from 64.42 to 89.09 in MMF group. Twenty-four-hour urinary protein (gm/1.73m2) reduced from 4.47 to 0.94...Continue Reading

Associated Clinical Trials

References

Mar 6, 1986·The New England Journal of Medicine·H A AustinJ L Decker
Nov 14, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·C Ponticelli
May 31, 2001·Kidney International·C C NajafiUNKNOWN Lupus Nephritis Collaborative Study Group
Jan 30, 2004·Journal of the American Society of Nephrology : JASN·Jan J WeeningMichio Nagata
Nov 25, 2005·The New England Journal of Medicine·Ellen M GinzlerGerald B Appel
Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Feb 20, 2007·Lancet·David P D'CruzGraham R V Hughes
Apr 5, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bin ZhuHaiJin Yu
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Michael WalshBrenda R Hemmelgarn
Nov 16, 2007·Kidney International·P Bhat, J Radhakrishnan
Apr 17, 2009·Journal of the American Society of Nephrology : JASN·Gerald B AppelUNKNOWN Aspreva Lupus Management Study Group
Nov 6, 2010·Journal of the American Society of Nephrology : JASN·Andrew S Bomback, Gerald B Appel
Jan 18, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Harini BagavantUmesh Deshmukh
Nov 28, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lorna K HendersonAngela C Webster
Feb 3, 2015·Respirology : Official Journal of the Asian Pacific Society of Respirology·Omer S B Alamoudi, Suzan M Attar

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
biopsy

Clinical Trials Mentioned

NCT03200002

Software Mentioned

SAS University Studio
SIEMENS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.